As far as the stability study, that is completely NR’s mess up. As soon as a new dose is used, that should immediately signal a new stability study or at least put it on your radar. The test is basically storing several doses in a freezer and rerunning the quality control assays after certain periods of time. Companies run long stability studies to help improve their supply chain. NP kindly made it clear/hinted it was NR’s fault in the shareholders meeting, if I remember correctly.
